Choline Alphoscerat (Gliatilin) in the pathogenetic therapy of Alzheimer’s disease
https://doi.org/10.31363/2313-7053-2018-4-93-99
Abstract
Alzheimer’s disease (Alzheimer’s type dementia) (BA) is a primary progressive neurodegenerative disease of the brain with characteristic clinical and pathological features, individual characteristics of the course and severity of symptoms, as well as multiple converging etiopathogenetic mechanisms. Te most successfully developed at the present time are compensatory (replacement) therapy aimed at overcoming the neurotransmitter defciency in various neuronal systems, which are more or less affected by the development of Alzheimer’s disease. Choline alfoscerat (Gliatilin) is a cholinomimetic of central action with a predominant effect on the central nervous system. In the process of metabolism, the molecule of Gliatilin (choline alphoscerate) undergoes cleavage into choline (40.5%) and glycerophosphate. Te resulting choline stimulates the synthesis of acetylcholine, which improves the transmission of nerve impulses in cholinergic neurons, and glycerophosphate stimulates the appearance of phosphatidylcholine, which restores the phospholipid composition of neuronal membranes, improving their plasticity. Glitatylin (choline alfoscerate) has a stimulating effect on cognitive functions and improves memory and attention, leads to the correction of psycho-emotional disorders. Glitatilin (choline alphosceratus) positively increases in cerebral blood flow, accelerates metabolism and activates structure brain reticular formation. Te effect on glia is expressed in suppressing the activation of inflammation, reducing intracellular edema and reducing microvascular permeability. Choline alfostserat (Gliatilin) can be recommended for use in patients with asthma as monotherapy, and about complex treatment.
About the Authors
D. V. Zaharov
V.M. Bekhterev National medical research center of psychiatry and neurology
Russian Federation
Russian Federation
V. A. Mihailov
V.M. Bekhterev National medical research center of psychiatry and neurology
Russian Federation
Russian Federation
Y. V. Kotsiubinskaya
V.M. Bekhterev National medical research center of psychiatry and neurology
Russian Federation
Russian Federation
References
1. Balunov O.A., Mikhailov V.A., Sadov O.G., AlemasovaA.Yu. Te effectiveness of gliatilin in the system of rehabilitation measures in post-stroke patients with mental disorders. v sb. «Sosudistayapatologiyanervnoisistemy». —SPb.—1998.—S.173- 174. (In Rus.).
2. Balunov O.A., Chernenkov V.P., Mikhailov V.A., Sadov O.G., AlemasovaA.Yu. A study of the clinical efcacy of gliatilin in patients with multi-infarction dementia v sb. «Neotlozhnayanevrologiya» materialy nauchnoprakticheskoi konferentsii. — Omsk. — 1998. — S.7-9. (InRus.).
3. Gusev E.I., Skvortsova V.I. Ischemia of the brain.—M.
4. Levin O.S., Batukayeva L.A., Anikina M.A., Yushchenko N.A. Efcacy and safety of choline-alfoserate (Cereton) in patients with Parkinson’s disease with cognitive impairment..— NeurosciBehavPhysiology. — 2011. — T.41. — S.47-51. (InRus.).
5. Chukanova E.I., Chukanova A.S. Separate mechanisms of the pathogenesis of the formation of cerebral insufciency. Zhur. Farmateka (kardiologiya / nevrologiya). —2014. — T.13. —S.14–20. (InRus.).
6. Chukanova E.I., Chukanova A.S. // Choline alfoscerat (Delecit) as one of the treatment of cognitive disorders // Meditsinskiialfavit. — 2016. — №14. — S.12-16. (InRus.).
7. Alzheimer’s Association. Alzheimer’s disease facts and fgures. Alzheimers Dement. — 2013. — Vol.9. — P. 208-267. DOI: 10.1016/j.jalz.2013.02.003.
8. Amenta F, Tayebati SK, Vitali D, Di Tullio MA. Association with the cholinergic precursor choline alphoscerate and the cholinesterase inhibitor rivastigmine: an approach for enhancing cholinergic neurotransmission // Mech Ageing Dev. — 2006. — V.127. — P.173-179. DOI: 10.1016/j.mad.2005.09.017
9. Bartus R.T., Dean III R.L., Beer B., Lippa A.S. Te cholinergic hypothesis of geriatric memory dysfunctions // Science. — 1982. — V. 217. — P. 408-417. DOI: 10.1126/science.7046051}.
10. De Jesus Moreno M. Cognitive improvement in mild to moderate Alzheimer’s dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, doubleblind, randomized, placebo-controlled trial // ClinTer. — 2003. — vol.25. — P.178—193. PMID: 12637119.
11. De la Monte SM. Insulin resistance and Alzheimer’s disease // BMB Rep. — 2009. — V.42. — P.475-481. DOI: 10.5483/BMBRep.2009.42.8.475
12. Carotenuto A, Rea R, Traini E, Fasanaro A, et al. Te Effect of the Association between Donepezil and Choline Alphoscerate on Behavioral Disturbances in Alzheimer’s Disease: Interim Results of the ASCOMALVA Trial // Journal of Alzheimer’s Disease. — 2017. — V.56. — P.805-815. DOI: 10.3233/JAD-160675
13. Cetinkaya M., Cansev M., Cekmez F., Tayman C., et al. CDP-choline reduces severity of intestinal injury in a neonatal rat model of necrotizing enterocolitis //J Surg Res. — 2013. — V.183. — P.119–128. DOI: 10.1016/j.jss.2012.11.032
14. Colucci L., Bosco M., Ziello A.R., Rea R., et al. Effectiveness of nootropic drugs with cholinergic activity in treatment of cognitive defcit: a review // J of Experimental Pharmacology. — 2012. — V.4. — P.163-172. DOI : 10.2147/JEP.S35326
15. Everitt B.J., Robbins T.W. Central cholinergic systems and cognition // Annu Rev Psychol. — 1997. — V.48. — P.649-684. DOI: 10.1146/annurev.psych.48.1.649.
16. Gauthier S. Advances in the pharmacotherapy of Alzheimer’s disease // CMAJ. — 2002. — V. — 166. — P.616-623. PMCID: PMC99406 http://www.cmaj.ca/content/166/5/616
17. Gurun M.S., Parker R., Eisenach J.C., Vincler M. Te effect of peripherally administered CDP-choline in an acute inflammatory pain model: Te role of alpha 7 nicotinic acetylcholine receptor // Anesth. Anal. — 2009. — V.108. — P.1680–1687. DOI: 10.1213/ane.0b013e31819dcd08.
18. Naderali E.K., Ratcliffe S.H., Dale M.C. Obesity and Alzheimer’s disease: a link between body weight and cognitive function in old age // American Journal of Alzheimers Disease and Other Dementias. — 2010. — V.24. — P.445-449. DOI: 10.1177/1533317509348208.
19. Parnetti L., Mignini F., Tomassoni D., Traini E., et al. Cholinergic precursors in the treatment of cognitive impairment of vascular origin: ineffective approaches or need for re-evaluation?// J Neurol Sci. — 2007. — V.257. — P.264-269. DOI: 10.1016/j.jns.2007.01.043.
20. Parrish W.R., Rosas-Ballina M., GallowitschPuerta M., Ochani M., et al. Modulation of TNF release by choline requires alpha7 subunit nicotinic acetylcholine-mediated signalling // Mol Med.- 2008.- V. 14.- P. 567–574. DOI: 10.2119/2008-00079.Parrish.
21. Pinto T., Lanctot K.L., Herrmann N. Revisiting the cholinergic hypothesis of behavioral and psychological symptoms dementia of the Alzheimer’s type // Ageing Res Rev.- 2011.- V. 10.- P. 404-412. DOI: 10.1016/j.arr.2011.01.003.
22. Rocchi A., Orsucci D., Tognoni G., Ceravolo R. et al. Te role of vascular factors in lateonset sporadic Alzheimer’s disease. Genetic and molecular aspects // Current Alzheimer Research. — 2009. — V.6. — P.224-237. DOI : 10.2174/156720509788486644.
23. Roriz-Filho S.J., Sá-Roriz T.M., Rosset I., Camozzato A.L. et al. (Pre)diabetes, brain aging, and cognition // BiochimBiophysActa. — 2009. — V. 1792. — P. 432-443. DOI: 10.1016/j.bbadis.2008.12.003.
24. Schneider L.S. Discontinuing donepezil or starting memantine for Alzheimer’s disease // N Engl J Med. — 2012. — V.3. — P.957-959. DOI: 10.1371/journal.pone.0046669.
25. Tayebati, S.K., Amenta, F. Choline-containing phospholipids: Relevance to brain functional pathways // ClinChem Lab Med. — 2013. — V.51. — P.513–521. DOI: https://doi.org/10.1515/cclm-2012-0559.
26. Tayebati S.K., Di Tullio M.A, Tomassoni D., Amenta F. Neuroprotective effect of treatment with galantamine and choline alphoscerate on brain microanatomy in spontaneously hypertensive rats // J Neurol Sci. — 2009. — V.283. — P.187-194. DOI: https://doi.org/10.1016/j.jns.2009.02.349.
27. Tayebati S.K., Tomassoni D., Di Stefano A., Sozio P. et al. Effect of choline-containing phospholipids on brain cholinergic transporters in the rat // J Neurol Sci. — 2011. — V. 302. — P. 49-57. DOI: 10.1016/j.jns.2010.11.028
28. Tomassoni D., Avola R., Mignini F., Parnetti L. et al. Effect of treatment with choline alphoscerate on hippocampus microanatomy and glial reaction in spontaneously hypertensive rats // Brain Res. — 2006. — V.1120. — P.183-190. DOI: 10.1016/j.brainres.2006.08.068.
29. Trabace L., Coluccia A., Gaetani S. et al. In vivo neurochemical effects of the acetylcholinesterase inhibitor ENA713 in rat hippocampus // Brain Res. — 2000. — V.865. — P.268-271. DOI: 10.1016/s0006-8993(00)02266-6.
30. Tracey K.J. Physiology and immunology of the cholinergic anti-inflammatory pathway // J ClinInvestig. — 2007. — V.117. — P.289–296. DOI: 10.1172/JCI30555.
31. Tracey K.J. Reflex control of immunity // Nat Rev Immunol. — 2009. — V.9. — P.418–428. DOI: 10.1038/nri2566.
Review
For citations:
Zaharov D.V., Mihailov V.A., Kotsiubinskaya Y.V. Choline Alphoscerat (Gliatilin) in the pathogenetic therapy of Alzheimer’s disease. V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY. 2018;(4):93-99. (In Russ.) https://doi.org/10.31363/2313-7053-2018-4-93-99
Views:
1781
Email this article 